TY - JOUR
T1 - Parallels in Sepsis and COVID-19 Conditions
T2 - Implications for Managing Severe COVID-19
AU - Olwal, Charles Ochieng’
AU - Nganyewo, Nora Nghuchuzie
AU - Tapela, Kesego
AU - Djomkam Zune, Alexandra Lindsey
AU - Owoicho, Oloche
AU - Bediako, Yaw
AU - Duodu, Samuel
N1 - Publisher Copyright:
© Copyright © 2021 Olwal, Nganyewo, Tapela, Djomkam Zune, Owoicho, Bediako and Duodu.
PY - 2021/2/3
Y1 - 2021/2/3
N2 - Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.
AB - Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.
KW - COVID-19
KW - SARS-CoV-2
KW - coronavirus
KW - cytokine storm
KW - hypovolemia
KW - immunosuppression
KW - sepsis
UR - http://www.scopus.com/inward/record.url?scp=85101089116&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2021.602848
DO - 10.3389/fimmu.2021.602848
M3 - Article
C2 - 33613574
AN - SCOPUS:85101089116
SN - 1664-3224
VL - 12
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 602848
ER -